Literature DB >> 23264675

Prognostic value of body mass index for patients undergoing esophagectomy for esophageal squamous cell carcinoma.

Yufeng Cheng1, Nana Wang, Kai Wang, Jianbo Wang, Bingxu Tan, Yibin Jia, Yan Dou, Jinming Yu.   

Abstract

OBJECTIVE: The correlation between high body mass index and outcomes after esophagectomy has not been systematically addressed. Some studies have shown that patients with a high body mass index had better overall survival and disease-free survival compared with those with a normal/low body mass index, whereas others have shown that the body mass index was not of prognostic value.
METHODS: Ninety-nine patients with esophageal squamous cell carcinoma were retrospectively reviewed in this study. Patients' postoperative overall and disease-free survivals were compared between the two groups (body mass index <24.00 kg/m(2) and body mass index ≥24.00 kg/m(2)).
RESULTS: There were 66 patients in the low/normal body mass index group (body mass index <24.00 kg/m(2)) and 28 patients in the high body mass index group (body mass index ≥24.00 kg/m(2)). Although disease recurrence were more frequent in the high body mass index group vs. the low/normal body mass index group, there was no significant difference noted (60.7%, 40.9%, P = 0.078). The 3-year overall survival rates were 60.6% in the low/normal body mass index group and 57.1% in the high body mass index group (P = 0.392). The 3-year disease-free survival rates were higher in the low/normal body mass index group vs. the high body mass index group (56.1%, 39.3%, P = 0.048). On multivariate analysis, the number of lymph node metastases (hazard ratio: 1.192, 95% confidence interval: 1.076-1.320, P = 0.001) was recognized as an independent prognostic factor for overall survival. Both body weight loss (hazard ratio: 2.153, 95% confidence interval: 1.027-4.511, P = 0.042) and the number of lymph node metastases (hazard ratio: 1.669, 95% confidence interval: 1.297-2.146, P < 0.001) were significantly and independently associated with disease-free survival.
CONCLUSIONS: Our results suggest that high body mass index appears to shorten disease-free survival in esophageal squamous cell carcinoma patients and further studies are needed to detect the mechanism.

Entities:  

Mesh:

Year:  2012        PMID: 23264675     DOI: 10.1093/jjco/hys212

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  5 in total

Review 1.  Cachexia in patients with oesophageal cancer.

Authors:  Poorna Anandavadivelan; Pernilla Lagergren
Journal:  Nat Rev Clin Oncol       Date:  2015-11-17       Impact factor: 66.675

2.  Excessive Pretreatment Weight Loss Is a Risk Factor for the Survival Outcome of Esophageal Carcinoma Patients Undergoing Radical Surgery and Postoperative Adjuvant Chemotherapy.

Authors:  Xiao-Li Yu; Jin Yang; Ting Chen; Yi-Min Liu; Wei-Ping Xue; Ming-Hui Wang; Shou-Min Bai
Journal:  Can J Gastroenterol Hepatol       Date:  2018-01-28

3.  Impact of Weight Loss on Patients with Locally Advanced Esophageal and Esophagogastric Junction Cancers Treated with Chemoradiotherapy.

Authors:  Jirapath Wiwitkeyoonwong; Chuleeporn Jiarpinitnun; Pitichote Hiranyatheb; Nuttapong Ngamphaiboon
Journal:  Asian Pac J Cancer Prev       Date:  2021-12-01

4.  Influence of body mass index on the long-term outcomes of patients with esophageal squamous cell carcinoma who underwent esophagectomy as a primary treatment: A 10-year medical experience.

Authors:  Wenhao Ji; Weihui Zheng; Bo Li; Caineng Cao; Weimin Mao
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

5.  Prognostic value of preoperative weight loss-adjusted body mass index on survival after esophagectomy for esophageal squamous cell carcinoma.

Authors:  Han-Lu Zhang; Yu-Shang Yang; Jia-Nan Duan; Qi-Xin Shang; Song-Lin He; Yi-Min Gu; Wei-Peng Hu; Wen-Ping Wang; Yang Hu; Yun Wang; Yong Yuan; Long-Qi Chen
Journal:  World J Gastroenterol       Date:  2020-02-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.